Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon. - Suppr | 超能文献

Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.

作者信息

Bounameaux H M, Hellemans H, Verhaeghe R, Dequeker J

出版信息

J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):975-6. doi: 10.1097/00005344-198409000-00037.

DOI:10.1097/00005344-198409000-00037

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.

J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):975-6. doi: 10.1097/00005344-198409000-00037.

2

Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker.

Boll Chim Farm. 1985 Oct;124(10):121S-124S.

3

Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.使用5-羟色胺2受体拮抗剂酮色林治疗雷诺现象。

Br Med J (Clin Res Ed). 1982 Oct 16;285(6348):1069-71. doi: 10.1136/bmj.285.6348.1069.

4

Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.用酮色林（一种5-羟色胺2（5-HT2）受体的选择性拮抗剂）治疗雷诺现象。

Arthritis Rheum. 1984 Feb;27(2):139-46. doi: 10.1002/art.1780270204.

5

Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.用酮色林治疗结缔组织病患者的雷诺现象。

Br Med J (Clin Res Ed). 1984 Sep 8;289(6445):577-9. doi: 10.1136/bmj.289.6445.577.

6

Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.慢性酮色林治疗对雷诺现象患者血清素诱导的血小板聚集的影响。

Eur J Clin Pharmacol. 1990;39(3):289-90. doi: 10.1007/BF00315113.

7

The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.选择性5-羟色胺S2受体拮抗剂酮色林在雷诺现象治疗中的应用。

Eur J Vasc Surg. 1988 Dec;2(6):371-5. doi: 10.1016/s0950-821x(88)80014-8.

8

Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.酮色林治疗与系统性硬皮病相关的雷诺现象。

Br J Dermatol. 1988 Dec;119(6):751-4. doi: 10.1111/j.1365-2133.1988.tb03498.x.

9

Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.酮色林对进行性系统性硬化症中雷诺现象的影响：一项双盲试验。

Drugs Exp Clin Res. 1985;11(9):659-63.

10

Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.酮色林治疗进行性系统性硬化症中的雷诺现象。

Cochrane Database Syst Rev. 2000;1998(2):CD000954. doi: 10.1002/14651858.CD000954.

引用本文的文献

1

Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.静脉注射酮色林改善冷诱导的雷诺现象：一项双盲交叉研究。

Arch Dermatol Res. 1986;279(1):3-7. doi: 10.1007/BF00404349.

2

Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.酮色林治疗与原发性和继发性雷诺现象患者的血清素

Eur J Clin Pharmacol. 1988;35(4):419-21. doi: 10.1007/BF00561375.

3

Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.酮色林。对其药效学和药代动力学特性以及在高血压和外周血管疾病中的治疗潜力的综述。

Drugs. 1990 Dec;40(6):903-49. doi: 10.2165/00003495-199040060-00010.